Talquetamab,Teclistamab,Daratumumab
Genmab,Janssen
['mmsm', 'effector ']
tec + tal with an 85% orr in r/r extramedullary myeloma! needs longer fu and safety data but dual bispecific combination seems feasible and exciting! check out our experience in extramedullary myeloma and immune effector therapies: #asco23 #mmsm 
Hematology/Oncology Fellow @MayoHemeOnc | Former @MAYOMN_IMRES and @TataMemorial | @ManUtd and @bcci| Tweets are my own|